Catalog No.
Product Name
Application
Product Information
Citations
-
ADC/PROTAC Linkers
Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br serves as a versatile drug-linker conjugate for antibody-drug conjugate (ADC) applications. This reagent enables the synthesis of conjugates targeting the CD40 antigen, facilitating the development of targeted therapies. Its unique structure supports the design of PROTACs and other innovative bio-conjugates, contributing to advances in cancer research and immunotherapy. -
Drug-Linker Conjugates for ADC
MCC-DM1 is a potent drug-linker conjugate targeting antibody-drug conjugates (ADCs) such as Anti-CD22-MCC-DM1. This compound is designed to facilitate selective delivery of cytotoxic agents to target cells, enhancing therapeutic efficacy while minimizing systemic toxicity. MCC-DM1 can be detected in various biological matrices, including rat and human plasma, feces, and other tissues, making it suitable for pharmacokinetic and bioavailability studies in clinical research applications. -
Drug-Linker Conjugate for ADC
XMT-1519 conjugate-1 is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound facilitates the conjugation with the HER-2 monoclonal antibody Calotatug (XMT-1519), enabling the targeted delivery of therapeutic agents to cancer cells that express the HER-2 receptor. It is an essential component for the synthesis of ADCs aimed at enhancing anticancer efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of the linker peptide Ac-Lys-Val-Cit-PABC, which facilitates the selective delivery of the potent microtubule inhibitor MMAE, known for its ability to disrupt tubulin polymerization. Ideal for ADC research applications, it supports studies focused on targeted cancer therapies and the mechanism of action of ADCs. -
Drug-Linker Conjugate for ADC
MC-DM1 is a drug-linker conjugate that combines the potent microtubule-disrupting agent DM1 with the stable linker MC, designed for application in antibody-drug conjugates (ADCs). This compound effectively facilitates targeted delivery of cytotoxic agents to malignant cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. MC-DM1 is suitable for research focused on cancer treatment and the development of next-generation ADCs. -
Drug-Linker Conjugate for ADC
DM4-SMCC is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing the potent antitubulin agent DM4. This conjugate exhibits significant antitumor activity by employing the non-cleavable SMCC linker to facilitate targeted delivery to cancer cells. DM4-SMCC is essential for research involving ADC development and the exploration of targeted cancer therapies. -
Drug-linker Conjugate for ADC
P5(PEG24)-VC-PAB-Exatecan is a drug-linker conjugate that combines the potent DNA Topoisomerase I inhibitor, Exatecan, with the P5(PEG24)-VC-PAB linker, designed for use in antibody-drug conjugate (ADC) applications. This compound demonstrates significant cytotoxicity against tumor cells, making it a valuable tool for cancer research and development. Its unique structure facilitates targeted delivery of Exatecan, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
MAL-di-EG-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a specialized linker (MAL-di-EG-Val-Cit-PAB) with MMAE, a potent tubulin inhibitor, to enable targeted delivery of cytotoxic agents to cancer cells. This compound is utilized in research focused on developing more effective ADCs for cancer therapy by minimizing off-target effects and enhancing therapeutic efficacy. -
Drug-Linker Conjugate for ADC
Mal((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB-Exatecan is a sophisticated drug-linker conjugate that targets DNA Topoisomerase I with the potent inhibitor Exatecan. This compound is designed for use in antibody-drug conjugates (ADCs), providing enhanced specificity and efficacy in cancer therapy. Its unique linker structure facilitates the stable attachment of therapeutic agents to antibodies, improving targeting and reducing systemic toxicity in research applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It combines the DBCO-PEG4-VC-PAB linker with the potent cytotoxin DMEA-PNU-159682, which includes active metabolites of nemorubicin. This compound leverages click chemistry, featuring a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 serves as an effective tool in targeted cancer therapy research and the development of innovative ADCs. -
Drug-Linker Conjugate for ADC
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, comprising a linker moiety and Exatecan, a potent topoisomerase I inhibitor. This compound facilitates the synthesis of ADC molecules, enabling targeted delivery of cytotoxic agents to tumor cells while minimizing off-target effects. Its unique structure allows for effective internalization and release of the active drug in the cellular environment, making it valuable for studies in cancer therapeutics and drug development. -
Drug-Linker Conjugates for ADC
Biotin-PEG7-Maleimide is a biotinylation reagent designed for conjugation with thiol groups (SH). This compound serves as a versatile linker in drug-linker conjugates for antibody-drug conjugates (ADCs), facilitating efficient targeting and delivery of therapeutic agents. Its unique structure allows for enhanced stability and bioavailability in various research applications. -
Drug-Linker Conjugate for ADC
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a cleavable linker bonded to Exatecan. This compound facilitates targeted delivery of cytotoxic agents by linking to anti-Her3 antibodies, enabling enhanced therapeutic efficacy against Her3-expressing tumors. It is a valuable tool for researchers focusing on ADC development and cancer therapy. -
Drug-Linker Conjugates For ADC
TL033 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises a linker and a bioactive small molecule toxin, enabling its conjugation with Sacituzumab, an anti-Trop-2 antibody, to synthesize BT001021. BT001021 exhibits anti-cancer activity against various malignancies, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
CB07-Exatecan is a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) synthesis. This conjugate demonstrates potent anti-cancer activity by inhibiting the growth of HER2-positive cancer cells when used in combination with trastuzumab. CB07-Exatecan is a valuable tool for researchers investigating targeted cancer therapies and the development of ADCs in oncology. -
Drug-Linker Conjugate for ADC
BCN-HS-PEG2(vcPABC-MMAE)2 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound incorporates a cleavable linker and the microtubule inhibitor MMAE, facilitating targeted delivery of cytotoxic agents to cancer cells. BCN-HS-PEG2(vcPABC-MMAE)2 is vital for researchers involved in the development and synthesis of ADCs, enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-Doxorubicin is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features a maleimide moiety, enabling conjugation with thiol-containing molecules. Doxorubicin, an anthracycline antibiotic, exhibits potent antineoplastic activity, making this conjugate a valuable tool for targeted cancer therapy research and development. -
Drug-Linker Conjugates for ADC Inhibitor
PSMA-Val-Cit-PAB-MMAE is a targeted drug-linker conjugate that utilizes monomethyl auristatin E (MMAE) to selectively inhibit prostate-specific membrane antigen (PSMA). This compound demonstrates potent cytotoxicity against PSMA-expressing tumor cells, making it a valuable tool for developing antibody-drug conjugates (ADCs) in prostate cancer therapy. Its design enhances the therapeutic efficacy while minimizing off-target effects in cancer treatment research. -
Drug-Linker Conjugate for ADC
VcMMAE-Deruxtecan is a targeted drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines a cytotoxic microtubule inhibitor, MMAE, with Exatecan, a DNA topoisomerase I inhibitor, facilitating precise targeting of cancer cells. VcMMAE-Deruxtecan is primarily utilized in the synthesis of ADCs, contributing to advancements in cancer therapeutics. -
Drug-Linker Conjugate for ADC
Aminocaproyl-Val-Cit-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound utilizes a cleavable linker to facilitate the selective release of the cytotoxic agent MMAE upon internalization and proteolytic cleavage, enhancing targeted delivery to cancer cells. It is suitable for research focused on developing and optimizing ADCs for therapeutic purposes in oncology. -
Drug-Linker Conjugate for ADC
GGFG-PAB-Exatecan is a drug-linker conjugate that combines the cytotoxic agent Exatecan with the linker GGFG-PAB. This compound is designed for the synthesis of antibody-drug conjugates (ADCs), facilitating targeted delivery of cytotoxic agents to cancer cells. Its unique structure can enhance the therapeutic efficacy of ADCs while minimizing off-target effects, making it a valuable reagent for cancer research and drug development applications. -
Drug-Linker Conjugates for ADC
Mal-Phe-C4-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization, which serves as the cytotoxic payload. Its structure is optimized for effective delivery and targeted therapy in cancer research, making it an essential reagent for developing and studying ADCs. -
Drug-Linker Conjugates for ADC
APL-1081 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features the Mal-Exo-EEVC peptide linker that facilitates effective targeting and delivery, combined with the potent tubulin polymerization inhibitor MMAE. This compound demonstrates significant biological activity by disrupting microtubule dynamics, making it valuable for research focused on cancer therapeutics and ADC development. -
Drug-Linker Conjugates for ADC
Mal-C2-Gly3-EDA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker, Mal-C2-Gly3-EDA, which facilitates the targeted delivery of the cytotoxic agent PNU-159682 to specific cells. Its robust structure allows for effective release of the potent cytotoxin upon internalization, making it suitable for cancer research and therapeutic development in targeted therapies. -
Drug-Linker Conjugate for ADC
DBCO-β-Glu-PEG12-Exatecan serves as a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound acts as a potent inhibitor of topoisomerase I, effectively disrupting DNA replication and transcription processes. Its unique structure allows for targeted delivery in therapeutic applications, making it suitable for research in cancer treatment and other malignancies. This reagent provides a valuable tool for the development and optimization of ADC formulations. -
Drug-Linker Conjugate for ADC
GGFG-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of the GGFG-PAB linker, which facilitates targeted delivery, and the potent microtubule inhibitor MMAE, enhancing its therapeutic efficacy. GGFG-PAB-MMAE is utilized in research for developing effective cancer therapies through targeted cytotoxicity mechanisms. -
Drug-Linker Conjugates for ADC
Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It incorporates the potent anti-mitotic agent, monomethyl auristatin E (MMAE), via a cleavable linker that facilitates targeted delivery. This reagent features an azide group and is suitable for click chemistry reactions, specifically copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne-containing molecules, as well as DBCO or BCN groups. Its use in ADC development underscores its significance in research focused on targeted cancer therapies. -
Drug-Linker Conjugate for ADC
Fmoc-GGFG-DXd is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It incorporates the Fmoc-GGFG linker and the potent DNA topoisomerase I inhibitor DXd. This compound is intended for use in targeted cancer therapies, facilitating the delivery of cytotoxic agents specifically to tumor cells while minimizing systemic toxicity. Its unique structure supports research in the development and optimization of ADC formulations for enhanced therapeutic efficacy. -
Drug-Linker Conjugates For ADC
Deruxtecan analog 2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound comprises Camptothecin, a well-known topoisomerase I inhibitor that exhibits potent antineoplastic activity against various cancers, including colorectal, breast, lung, and ovarian tumors. Deruxtecan analog 2 serves as a valuable reagent for the synthesis of anti-FGFR2 ADCs, advancing research in targeted cancer therapeutics. -
Drug-Linker Conjugates for ADC
SPP-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes DM1, a potent microtubule-disrupting agent, linked through the SPP linker to deliver targeted antitumor efficacy. This compound exhibits significant biological activity against malignant cells, making it relevant for cancer research and therapeutic development. SPP-DM1 is a valuable tool for studying the mechanisms of ADCs in oncology. -
Drug-Linker Conjugate for ADC
MC-VC-PABC-C6-α-Amanitin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent RNA polymerase IIα inhibitor α-Amanitin linked through a MC-VC-PABC-C6 linker. This compound exhibits significant cytotoxic activity against cancer cells by disrupting transcriptional processes. It is an essential tool for researchers focusing on targeted cancer therapies and ADC development. -
Drug-Linker Conjugate for ADC
LacNAc-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound is specifically engineered for attachment at the N-glycosylation site of Trastuzumab, utilizing WT Endo-S2 for assembly. LacNAc-VC-PAB-MMAE facilitates targeted delivery of cytotoxic agents, enhancing therapeutic efficacy in cancer treatment applications. Its innovative design supports research in ADC optimization and development for improved specificity and reduced systemic toxicity. -
Drug-Linker Conjugate for ADC
MCC-AAQ-Exa is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), formed through the condensation of a linker with Exatecan. The MCC component features a maleimide fragment, facilitating efficient conjugation to antibodies. This reagent is essential for researchers developing targeted therapies, enabling the precise delivery of cytotoxic agents to tumor cells while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
DBM-GGFG-NH-O-CO-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, functioning primarily as a topoisomerase I inhibitor. It is utilized in the synthesis of ADC molecules to effectively target and deliver cytotoxic agents to specific cell populations, enhancing therapeutic efficacy while minimizing systemic toxicity. This compound plays a vital role in cancer research by facilitating the development of targeted therapies. -
Drug-Linker Conjugates for ADC
Cys-MC-VC-PAB-MMAE is a cleavable drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). The linker comprises Cys-MC-VC-PAB, facilitating selective release of the potent tubulin inhibitor Monomethyl auristatin E (MMAE) upon internalization. This compound enhances the efficacy of ADCs by delivering chemotherapeutic payloads directly to target cells, thereby improving therapeutic outcomes in cancer research applications. -
Drug-linker Conjugates For ADC
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a specialized drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines a linker with Exatecan, a potent topoisomerase I inhibitor, to facilitate targeted delivery of the drug to cancer cells. It demonstrates significant cytotoxic activity by promoting DNA damage and cell apoptosis, making it a valuable tool in cancer research and therapeutic development. Applications include studies focused on ADC efficacy and specificity in treating various malignancies. -
Drug-Linker Conjugate for ADC
Mal-C6-α-Amanitin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features α-Amanitin, a potent inhibitor of RNA polymerase II, linked through the Mal-C6 spacer. Its primary biological activity includes significant antitumor effects, making it a valuable tool for targeted cancer therapies and research in oncology. -
Drug-Linker Conjugate for ADC
Mc-Phe-Lys-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the stable attachment of cytotoxic agents to antibodies, enhancing targeted delivery and minimizing systemic toxicity. Its use in ADC synthesis supports the development of novel therapeutic strategies in cancer research and treatment. -
ADC Linker
OH-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that incorporates a potent tubulin inhibitor, MMAE. This compound is designed for the synthesis of ADCs, facilitating targeted delivery of cytotoxic agents to cancer cells. Its unique structure allows for selective release of MMAE, enhancing therapeutic efficacy while minimizing off-target effects. This reagent is valuable for researchers developing novel ADCs in the field of cancer treatment. -
Drug-Linker Conjugates for ADC
Mal-va-mac-SN38 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, incorporating the potent cytotoxin SN-38 linked via a stable linker. This compound exhibits rapid and covalent binding to endogenous albumin in vivo, leading to the formation of HSA-va-mac-SN38. Demonstrating remarkable stability in human plasma, Mal-va-mac-SN38 has shown significant anti-tumor and anti-metastasis effects, providing a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
PB089 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a polyethylene glycol (PEG) unit along with a cleavable linker, which facilitates the delivery of the cytotoxic agent Exatecan to target cells. This compound is valuable for enhancing the therapeutic index of ADCs by improving selectivity and minimizing off-target effects in cancer research. -
Drug-Linker Conjugates for ADC
MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a peptide-based ADC linker with Exatecan, a potent DNA topoisomerase I inhibitor, enhancing targeted therapeutic efficacy. This conjugate is suitable for research into cancer treatment mechanisms and the development of ADCs, providing insights into tumor cell response to topoisomerase I inhibition. -
Drug-linker Conjugate for ADC
Val-Cit-PABC-DOX is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises Doxorubicin, a potent inhibitor of DNA topoisomerase I and II, linked through the Val-Cit-PABC linker technology. This compound facilitates targeted delivery of Doxorubicin, enhancing its therapeutic efficacy while minimizing off-target effects, making it a valuable tool for cancer research and development. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It features a potent tubulin inhibitor, MMAE, linked via a cleavable moiety, DBCO-PEG4-VA-PABC, facilitating targeted delivery to cancer cells. This conjugate is suitable for the synthesis of ADCs, demonstrating potential application in targeted cancer therapies by enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
(1R)-Deruxtecan is a potent drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing systemic toxicity. It is valuable in cancer research and development, particularly for optimizing ADC formulations and assessing their pharmacological profiles. -
Drug-Linker Conjugate for ADC
Fmoc-NMe-Val-Val-Dil-Dap-OH serves as an essential intermediate in the synthesis of drug-linker conjugates, specifically MC-MMAF. This compound is pivotal for the development of antibody-drug conjugates (ADCs), facilitating targeted drug delivery in therapeutic applications. Its unique structure supports the formation of stable linkages essential for effective ADC formation and enhances the specificity and efficacy of cancer therapies. -
Drug-Linker Conjugates For ADC
N3-PEG3-VC-PAB-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a potent tubulin inhibitor, MMAF, linked via the N3-PEG3-VC-PAB moiety. This compound serves as a click chemistry reagent, facilitating the copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with alkyne-containing molecules. Additionally, it can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN-functionalized compounds, making it valuable for targeted drug delivery and therapeutic development in cancer research. -
ADC Linker
IM-2 is a potent ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the efficient conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to cancer cells while minimizing systemic toxicity. This reagent is ideal for research applications focused on developing novel therapeutic modalities in oncology. -
Drug-Linker Conjugates for ADC
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a protease-cleavable MC-GGFG linker, allowing for targeted delivery and release of the cytotoxic agent camptothecin upon cleavage in the tumor microenvironment. Its structural design enhances therapeutic efficacy while minimizing systemic toxicity, making it a valuable tool for cancer research and development of targeted cancer therapies. -
Drug-Linker Conjugates for ADC
SC-VC-PAB-DM1 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs), employing DM1 (Mertansine), a potent tubulin inhibitor. This conjugate exhibits significant antitumor activity through targeted delivery, facilitating the precise release of the cytotoxic agent in malignant tissues. SC-VC-PAB-DM1 is suitable for research applications focused on cancer therapeutics and the development of effective ADCs.
